[Clinical study on SM-4300 in the field of internal medicine].
A new human gamma-globulin for intravenous use, SM-4300, was administered to 13 patients with infectious diseases. Five grams of SM-4300 was drip infused to each patient whose infection was not controlled by previous administered antibiotics. All of 13 patients had primary diseases besides infections. Thirteen patients were composed of 4 with pyelonephritis, 2 with pneumonia, 1 with bronchopneumonia, 1 with bronchitis, 1 with pyothorax, 2 with sepsis and 2 with cholecystitis. The results obtained were good in 3 cases, fair in 2 cases and poor in 7 cases. The results of a patient was not determined. No side effect was found including in laboratory findings.
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000628:therapy*; D001660:Biliary Tract Diseases / Q000628:therapy; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000009:adverse effects; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011550:Pseudomonas aeruginosa / Q000276:immunology; D012141:Respiratory Tract Infections / Q000628:therapy; D014552:Urinary Tract Infections / Q000628:therapy
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300